(0.33%) 5 116.74 points
(0.32%) 38 362 points
(0.38%) 15 988 points
(-0.99%) $83.02
(5.51%) $2.03
(0.33%) $2 354.90
(0.48%) $27.67
(4.13%) $960.20
(-0.26%) $0.932
(-0.45%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain...
Stats | |
---|---|
本日の出来高 | 240 995 |
平均出来高 | 138 824 |
時価総額 | 14.58M |
EPS | $0 ( 2024-04-04 ) |
次の収益日 | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.313 |
ATR14 | $0.0740 (8.03%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-15 | Nantahala Capital Management, Llc | Buy | 0 | Common Stock |
2023-07-20 | Nantahala Capital Management, Llc | Buy | 2 205 883 | 2023 Series A Warrants |
2023-07-20 | Nantahala Capital Management, Llc | Buy | 2 205 883 | 2023 Series B Warrants |
2023-07-20 | Nantahala Capital Management, Llc | Buy | 750 883 | 2023 Pre-Funded Warrants |
2024-03-15 | Nantahala Capital Management, Llc | Buy | 755 000 | Call Option (Right to Buy) |
INSIDER POWER |
---|
82.96 |
Last 92 transactions |
Buy: 3 436 001 | Sell: 171 828 |
ボリューム 相関
AcelRx Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
PDFS | -0.956 |
IDCC | -0.956 |
ALTR | -0.956 |
ANSS | -0.954 |
LPTH | -0.953 |
INTA | -0.952 |
SLMBP | -0.952 |
APXI | -0.952 |
SJ | -0.952 |
NCAC | -0.951 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
AcelRx Pharmaceuticals 相関 - 通貨/商品
AcelRx Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $651 000 |
総利益: | $651 000 (100.00 %) |
EPS: | $-0.000700 |
FY | 2023 |
収益: | $651 000 |
総利益: | $651 000 (100.00 %) |
EPS: | $-0.000700 |
FY | 2022 |
収益: | $1.77M |
総利益: | $-820 000 (-46.30 %) |
EPS: | $5.73 |
FY | 2021 |
収益: | $2.82M |
総利益: | $-935 000 (-33.18 %) |
EPS: | $-5.86 |
Financial Reports:
No articles found.
AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。